Diametric Capital’s Palisade Bio PALI Stock Holding History

Diametric Capital’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-51,874	Closed	-$90.8K	–	629
2026 Q1	$90.8K	Buy	+51,874	New	+$94.3K	0.02%	423

Other funds holding PALI

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Diametric Capital's PALI Position: Q2 2026 in Review

Diametric Capital sold out of Palisade Bio (PALI) in Q2 2026, closing a stake of 51,874 shares — an estimated $90.8K sold.

Diametric Capital first reported a position in PALI in Q1 2026 and held it in 1 quarter. The position peaked at $90.8K in Q1 2026. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

Diametric Capital reported no remaining Palisade Bio position as of Q2 2026 after selling out during the quarter.
Diametric Capital sold 51,874 Palisade Bio shares in Q2 2026, an estimated $90.8K.
Diametric Capital first reported a position in Palisade Bio in Q1 2026 and held it in 1 quarter.
Diametric Capital's Palisade Bio position peaked at $90.8K in Q1 2026.
124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.